Medicine Information

Cleven

Name: Cleven
Brand: Cleven
Rating: 4.5 (117 reviews)

Solution for Injection (Prefilled Syringe)6000 anti-Xa IU (equivalent to 60 mg)/0.6 mLAnticoagulants (Low Molecular Weight Heparins)ATC: B01AB05

Generic Name

Enoxaparin Sodium

Manufacturer

Square Pharmaceuticals Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
cleven 6000 anti xa injection	৳ 576.00	N/A

Description

Overview of the medicine

Cleven-6000 is a low molecular weight heparin (LMWH) used to prevent and treat blood clots (thrombosis). It contains enoxaparin sodium as its active ingredient.

Uses & Indications

Prophylaxis of deep vein thrombosis (DVT) in surgical and medical patients.

Treatment of DVT with or without pulmonary embolism (PE).

Prophylaxis of ischemic complications of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI).

Prevention of clot formation in the extracorporeal circulation during hemodialysis.

Dosage

Adults

DVT prophylaxis (surgical): 20 mg or 40 mg SC once daily. DVT/PE treatment: 1 mg/kg SC every 12 hours or 1.5 mg/kg SC once daily. Unstable angina/NSTEMI: 1 mg/kg SC every 12 hours.

Elderly

No dosage adjustment is generally required, but close monitoring of renal function is recommended.

Renal_impairment

Severe renal impairment (CrCl < 30 mL/min): Dose reduction is necessary. For treatment, 1 mg/kg SC once daily. For prophylaxis, 30 mg SC once daily.

How to Take

Administer by deep subcutaneous injection, preferably into the abdominal wall (alternating left and right sides) or the outer thigh. Do not inject intramuscularly. Do not mix with other injections.

Mechanism of Action

Enoxaparin binds to antithrombin III, which then inactivates Factor Xa (and to a lesser extent, Factor IIa/thrombin), preventing the formation and growth of blood clots.

Pharmacokinetics

Onset

Peak anti-Xa activity achieved within 3-5 hours after subcutaneous administration.

Excretion

Primarily excreted renally, with approximately 10% of the dose excreted as active fragments in urine.

Half life

Anti-Xa elimination half-life is approximately 4-5 hours after a single subcutaneous dose, and up to 7 hours after repeated dosing.

Absorption

Approximately 100% bioavailability after subcutaneous injection.

Metabolism

Primarily metabolized in the liver by desulfation and depolymerization into lower molecular weight species with reduced anticoagulant activity.

Side Effects

Contraindications

Hypersensitivity to enoxaparin, heparin, or porcine products.
Active major bleeding or conditions with a high risk of uncontrolled bleeding.
History of heparin-induced thrombocytopenia (HIT) with or without thrombosis.

Drug Interactions

Other thrombolytic agents

Significantly increased risk of hemorrhage.

NSAIDs (e.g., Ibuprofen, Diclofenac)

Increased risk of bleeding. Use with caution.

Oral anticoagulants (e.g., Warfarin)

Increased risk of bleeding. Close monitoring and careful transition are required.

Antiplatelet agents (e.g., Aspirin, Clopidogrel)

Increased risk of bleeding. Concomitant use should be with caution.

Storage

Store below 25°C. Do not freeze. Protect from light. Keep out of reach of children.

Overdose

Overdose may lead to hemorrhagic complications. The anticoagulant effects can be largely neutralized by the slow intravenous injection of protamine sulfate. However, protamine sulfate only partially neutralizes anti-Xa activity.

Pregnancy & Lactation

Pregnancy Category B. Enoxaparin does not cross the placental barrier. Use in pregnancy only if clearly needed after careful risk-benefit assessment. It is unlikely to be excreted into breast milk.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

1 x 0.6 mL prefilled syringe2 x 0.6 mL prefilled syringes5 x 0.6 mL prefilled syringes

Shelf Life

Typically 24 to 36 months from the date of manufacture when stored correctly.

Availability

Hospitals, Pharmacies

Approval Status

Approved

Patent Status

Off-patent

WHO Essential Medicine

Yes

Clinical Trials

Enoxaparin has been extensively studied in numerous clinical trials demonstrating its efficacy and safety for various indications, including DVT/PE prevention and treatment, and management of acute coronary syndromes.

Lab Monitoring

Complete Blood Count (CBC) including platelet count (before treatment and regularly during treatment).
Renal function (e.g., creatinine clearance) in patients with renal impairment.
Anti-Xa levels (in specific cases, not routinely needed).

Doctor Notes

Strictly monitor patients for signs of bleeding, especially in the elderly and those with renal impairment.
Adjust dose for severe renal impairment (CrCl < 30 mL/min).
Counsel patients on proper subcutaneous injection technique and the importance of reporting unusual bleeding or bruising.

Patient Guidelines

Follow proper injection technique as instructed by your healthcare provider.
Report any signs of unusual bleeding or bruising immediately.
Do not take any other medications, especially NSAIDs or blood thinners, without consulting your doctor.
Carry an identification card stating you are on enoxaparin.

Missed Dose Advice

If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double the dose.

Driving Precautions

Cleven-6000 is not known to affect the ability to drive or operate machinery.

Lifestyle Advice

Avoid activities that may increase your risk of bleeding or injury.
Inform all healthcare providers (including dentists) that you are taking this medication before any procedure.